Todos Medical Appoints Dr. Lauren Chung to its Boa
Post# of 30028
(Total Views: 371)
Posted On: 04/17/2020 7:38:41 AM
Todos Medical Appoints Dr. Lauren Chung to its Board of Directors
BY GlobeNewswire
— 7:30 AM ET 04/17/2020
Receives valuation of Alzheimer’s disease blood diagnostic LymPro Test Retains Donohoe Advisors to assist with Nasdaq CM™ listing process
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Todos Medical Ltd. ( TOMDF Loading...) , a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors. Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.
Todos Medical ( TOMDF Loading...) also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc. that is developing the proprietary immune-based Alzheimer’s disease blood diagnostic LymPro Test. Additionally, the Company announces that it has retained Donohoe Advisors to assist with its proposed listing on the Nasdaq CM™ national stock exchange in the United States.
“I am excited to join Todos at this key time in its growth trajectory,” said Dr. Chung. “With its recent entry into the COVID-19 testing space, Todos has taken a thoughtful, incremental approach to the market by focusing on the underlying biology of the disease as the field’s understanding is evolving, and how this will impact biomarker activation and relationships. This will help to inform physicians on how to use the tools we will be making available to diagnose, monitor and ultimately evaluate patient response to new therapies as they begin to enter the marketplace.”
She added, “This approach was born out of Todos Medical’s approach to Alzheimer’s disease given the lack of easy-to-use, effective diagnostic tools in that indication. With the enormous impact of COVID-19 and Alzheimer’s disease on the United States economy, Todos grasps the importance of sound science and following the data. I believe this approach will position the Company well for both near- and long-term success, and I look forward to assisting the Company in achieving its objective.”
Dr. Chung is the founder and CEO of MINLEIGH LLC, which is focused on identifying, evaluating and partnering with companies for investments and strategic, operational, and commercial opportunities. She has over 20 years of healthcare investment management, investment banking and advisory experience, and is currently a venture partner at Yozma Group Asia headquartered in South Korea.
Dr. Chung was a managing director in Healthcare Research at WestPark Capital. Previously, she was a co-founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at RBR Capital, Kingdon Capital and Pequot Capital. Earlier in her career, Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital. Dr. Chung has published in many leading peer-reviewed scientific journals.
As a current and former director of public and private companies, Dr. Chung brings a valuable perspective for the Company’s strategy and operations, as well as extensive scientific insights. Dr. Chung serves on the business review board of the Alzheimer’s Drug Discovery Foundation. Dr. Chung holds a Ph.D. in neuropathology from Columbia University-College of Physicians & Surgeons, and a BA with honors in Biochemistry and Economics from Wellesley College.
“We have been working with Dr. Chung for some time on an informal basis, and she has provided significant insight and guidance on positioning the Company for future growth,” said Gerald E. Commissiong, President & CEO of Todos Medical ( TOMDF Loading...). “We believe Alzheimer’s disease is effectively cancer of post-mitotic neurons, and this is the basis for aligning Todos’ cancer platform with the LymPro Alzheimer’s platform. Given Dr. Chung’s extensive background in the scientific and business communities in the Alzheimer’s space, and broad reach into the Asian capital markets, now is the time to bring Lauren on board as we build the Company’s profile as a leader in immune-based diagnostics for cancer, Alzheimer’s disease and COVID-19 in preparation for national stock exchange listing.”
https://www.globenewswire.com/news-release/20...ctors.html
BY GlobeNewswire
— 7:30 AM ET 04/17/2020
Receives valuation of Alzheimer’s disease blood diagnostic LymPro Test Retains Donohoe Advisors to assist with Nasdaq CM™ listing process
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Todos Medical Ltd. ( TOMDF Loading...) , a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors. Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.
Todos Medical ( TOMDF Loading...) also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc. that is developing the proprietary immune-based Alzheimer’s disease blood diagnostic LymPro Test. Additionally, the Company announces that it has retained Donohoe Advisors to assist with its proposed listing on the Nasdaq CM™ national stock exchange in the United States.
“I am excited to join Todos at this key time in its growth trajectory,” said Dr. Chung. “With its recent entry into the COVID-19 testing space, Todos has taken a thoughtful, incremental approach to the market by focusing on the underlying biology of the disease as the field’s understanding is evolving, and how this will impact biomarker activation and relationships. This will help to inform physicians on how to use the tools we will be making available to diagnose, monitor and ultimately evaluate patient response to new therapies as they begin to enter the marketplace.”
She added, “This approach was born out of Todos Medical’s approach to Alzheimer’s disease given the lack of easy-to-use, effective diagnostic tools in that indication. With the enormous impact of COVID-19 and Alzheimer’s disease on the United States economy, Todos grasps the importance of sound science and following the data. I believe this approach will position the Company well for both near- and long-term success, and I look forward to assisting the Company in achieving its objective.”
Dr. Chung is the founder and CEO of MINLEIGH LLC, which is focused on identifying, evaluating and partnering with companies for investments and strategic, operational, and commercial opportunities. She has over 20 years of healthcare investment management, investment banking and advisory experience, and is currently a venture partner at Yozma Group Asia headquartered in South Korea.
Dr. Chung was a managing director in Healthcare Research at WestPark Capital. Previously, she was a co-founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at RBR Capital, Kingdon Capital and Pequot Capital. Earlier in her career, Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital. Dr. Chung has published in many leading peer-reviewed scientific journals.
As a current and former director of public and private companies, Dr. Chung brings a valuable perspective for the Company’s strategy and operations, as well as extensive scientific insights. Dr. Chung serves on the business review board of the Alzheimer’s Drug Discovery Foundation. Dr. Chung holds a Ph.D. in neuropathology from Columbia University-College of Physicians & Surgeons, and a BA with honors in Biochemistry and Economics from Wellesley College.
“We have been working with Dr. Chung for some time on an informal basis, and she has provided significant insight and guidance on positioning the Company for future growth,” said Gerald E. Commissiong, President & CEO of Todos Medical ( TOMDF Loading...). “We believe Alzheimer’s disease is effectively cancer of post-mitotic neurons, and this is the basis for aligning Todos’ cancer platform with the LymPro Alzheimer’s platform. Given Dr. Chung’s extensive background in the scientific and business communities in the Alzheimer’s space, and broad reach into the Asian capital markets, now is the time to bring Lauren on board as we build the Company’s profile as a leader in immune-based diagnostics for cancer, Alzheimer’s disease and COVID-19 in preparation for national stock exchange listing.”
https://www.globenewswire.com/news-release/20...ctors.html
(2)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼